Skip to main content
Erschienen in: International Urogynecology Journal 2/2012

01.02.2012 | Original Article

Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ)

verfasst von: Lior Lowenstein, Leslie Rickey, Kimberly Kenton, Mary P. FitzGerald, Linda Brubaker, Mary Tulke, Joye Fordham, Elizabeth R. Mueller

Erschienen in: International Urogynecology Journal | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The aims of this study are (1) to assess the reliability (test–retest) of the Urgency Severity and Life Impact Questionnaire (USIQ) and (2) to test the effect of extended-release tolterodine on symptoms of urinary urgency using this validated instrument.

Methods

To measure reliability, women with overactive bladder (OAB) completed the USIQ on two separate occasions, prior to treatment for OAB. To assess the responsiveness, the USIQ participants completed the above-mentioned questionnaires prior to and following 4 weeks of treatment for OAB with extended-release tolterodine.

Results

USIQ-S and USIQ-QoL scores at the two visits did not differ significantly. Repeated measures of USIQ-S and USIQ-QoL demonstrated a moderate to excellent intraclass correlation coefficient (0.64–0.74; P < 0.0001 and 0.48–0.91, P < 0.0001, respectively). A significant decrease in mean USIQ-S and USIQ-QOL (71 ± 14 vs. 44 ± 19, P < 0.0001 and 51 ± 22 vs. 39 ± 10, P < 0.01, respectively) scores following treatment with tolterodine.

Conclusions

This valid, reliable measure can be used in clinical practice and research trials to measure urgency severity.
Literatur
1.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29:4–20PubMed Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29:4–20PubMed
2.
3.
Zurück zum Zitat Lowenstein L, FitzGerald MP, Kenton K, Hatchett L, Durazo-Arvizu R, Mueller ER, Goldman K, Brubaker L (2009) Evaluation of urgency in women, with a validated Urgency, Severity and Impact Questionnaire (USIQ). Int Urogynecol J Pelvic Floor Dysfunct 20:301–307PubMedCrossRef Lowenstein L, FitzGerald MP, Kenton K, Hatchett L, Durazo-Arvizu R, Mueller ER, Goldman K, Brubaker L (2009) Evaluation of urgency in women, with a validated Urgency, Severity and Impact Questionnaire (USIQ). Int Urogynecol J Pelvic Floor Dysfunct 20:301–307PubMedCrossRef
4.
Zurück zum Zitat Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef
5.
Zurück zum Zitat Herzog AR, Diokno AC, Brown MB, Normolle DP, Brock BM (1990) Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol 45:M67–M74PubMed Herzog AR, Diokno AC, Brown MB, Normolle DP, Brock BM (1990) Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol 45:M67–M74PubMed
6.
Zurück zum Zitat Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–139PubMedCrossRef Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–139PubMedCrossRef
7.
Zurück zum Zitat Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68:318–323PubMedCrossRef Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68:318–323PubMedCrossRef
8.
Zurück zum Zitat Santos JC, Telo ER (2010) Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol 63:197–213PubMed Santos JC, Telo ER (2010) Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol 63:197–213PubMed
9.
Zurück zum Zitat Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 63:1702–1714PubMedCrossRef Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 63:1702–1714PubMedCrossRef
10.
Zurück zum Zitat Freeman R, Hill S, Millard R, Slack M, Sutherst J (2003) Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102:605–611PubMedCrossRef Freeman R, Hill S, Millard R, Slack M, Sutherst J (2003) Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102:605–611PubMedCrossRef
11.
Zurück zum Zitat Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z (2008) Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180:1034–1041PubMedCrossRef Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z (2008) Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180:1034–1041PubMedCrossRef
12.
Zurück zum Zitat Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E (2005) The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95:335–340PubMedCrossRef Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E (2005) The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95:335–340PubMedCrossRef
Metadaten
Titel
Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ)
verfasst von
Lior Lowenstein
Leslie Rickey
Kimberly Kenton
Mary P. FitzGerald
Linda Brubaker
Mary Tulke
Joye Fordham
Elizabeth R. Mueller
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 2/2012
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-011-1531-z

Weitere Artikel der Ausgabe 2/2012

International Urogynecology Journal 2/2012 Zur Ausgabe

Mentors in Urogynecology

Urogynaecology: my view

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.